Company
Company description
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Quick Presentation Filters
Related Companies

Filter

      Loading ...

      Loading ...

      Loading ...

Filter

      Loading ...

      Loading ...

      Loading ...

Presentations (4)
Investor Presentation
February 2024
37 slides
Investor Presentation
December 2023
37 slides
Investor Presentation
October 2023
38 slides
Investor Presentation
July 2023
38 slides
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io